Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy

Immune checkpoint inhibitor-induced colitis: A comprehensive review

(2019) Aniruddh Som et al.   World Journal of Clinical Cases

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

(2019) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases

(2019) Suheil Albert Atallah-Yunes et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Immune-related pancreatitis associated with checkpoint blockade in melanoma

(2019) Johannes Kohlmann et al.   MELANOMA RESEARCH

Immune‐related Adverse Events in Cancer Patients

(2018) Daniel J. Pallin et al.   ACADEMIC EMERGENCY MEDICINE

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

(2018) Angeliki M. Stamatouli et al.   DIABETES

Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy

(2018) Thiru Prasanna et al.   Immunotherapy

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis

(2018) Yinghong Wang et al.   INFLAMMATORY BOWEL DISEASES

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

(2018) Eleonora De Martin et al.   JOURNAL OF HEPATOLOGY

Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

(2018) Yoh Zen et al.   MODERN PATHOLOGY

Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?

(2018) Kati Choi et al.   INFLAMMATORY BOWEL DISEASES

Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians

(2018) Adam T. Hryniewicki et al.   JOURNAL OF EMERGENCY MEDICINE

Immune Checkpoint Inhibitor-Associated Colits and Hepatitis

(2018) Haritha G. Reddy et al.   Clinical and Translational Gastroenterology

Diabetic ketoacidosis induced by a single dose of pembrolizumab

(2018) Julian Maamari et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

(2018) Mar Riveiro-Barciela et al.   JOURNAL OF HEPATOLOGY

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

(2018) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

(2018) Daniel H Johnson et al.   Journal for ImmunoTherapy of Cancer

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide

(2017) D. Berman et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer

(2016) J.C. Osorio et al.   ANNALS OF ONCOLOGY

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

(2016) L. Marthey et al.   Journal of Crohns & Colitis

Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report

(2016) Kazuhiko Ikeuchi et al.   LUNG CANCER

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunopathogenesis of IBD: current state of the art

(2015) Heitor S. P. de Souza et al.   Nature Reviews Gastroenterology & Hepatology

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

Gastroenteric tube feeding: Techniques, problems and solutions

(2014) Irina Blumenstein   WORLD JOURNAL OF GASTROENTEROLOGY

Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases

(2013) Marwan Ghabril et al.   Clinical Gastroenterology and Hepatology

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE